A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

Key facts

Sponsor

Jennerex Biotherapeutics

Principal Investigator

James Burke, MD, M.D., Ph.D

Jennerex Biotherapeutics

Intervention

JX-594 recombinant vaccina GM-CSF(biological)

Enrollment

129 enrolled

Eligibility

18 years · All sexes

Timeline

2008 – 2011

Study locations (30)

• Moores University of California San Diego Cancer Center, La Jolla, California, United States
• Chao Family Comprehensive Cancer Center, Orange, California, United States
• California Pacific Medical Center, San Francisco, California, United States
• Stanford Hospital and Clinics, Stanford, California, United States
• University of Chicago Medical Center, Chicago, Illinois, United States
• Billings Clinic, Billings, Montana, United States
• Saint Joseph's Hospital, Paterson, New Jersey, United States
• Montefiore Medical Center, The Bronx, New York, United States
• Gabrail Cancer Center, Canton, Ohio, United States
• University Hospitals Case Medical Center, Cleveland, Ohio, United States
• The Methodist Hospital Department of Surgery, Houston, Texas, United States
• University of Alberta, Edmonton, Alberta, Canada
• University of British Columbia, Vancouver, British Columbia, Canada
• Juravinski Cancer Centre, Hamilton, Ontario, Canada
• Ottawa Hopsital Research Institute, Ottawa, Ontario, Canada
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →